Sorainen has advised Esco Micro, a part of the Esco Group, on its acquisition of AT Medical. The transaction is expected to close in June 2018.
Esco Group is a Lithuania-based manufacturer and developer of innovative in vitro fertilization medical devices. Its products are currently distributed by Esco under the Esco Medical brand.
Under the terms of the agreement, Esco Micro will make an undisclosed payment for the remaining shares in AT Medical. The acquisition price represents an approximately 16 times return on investment on the first investment Esco made in AT Medical.
The Esco Group is a Singapore-based life science company. Medical is to be renamed Esco Medical Technologies and will continue operations as a separate legal entity within the Esco Group life science ecosystem.
Xiang Qian Lin, Group President & CEO of the Esco Group, said: “This strengthens our commitment to innovation within the fast-growing fertility technologies market, leveraging the Esco Group’s global network to accelerate product development and drive distribution. Furthermore, it is a successful example of Singaporean-European collaboration in the life sciences field.”
The Sorainen team was led by Partner Sergej Butov and included Ieva Krivickaite and Auguste Bucyte.